poisar

Stock

Vivos Therapeutics, Inc. VVOS

$0.41+1.01%

Overview

VVOS market data

Price History

VVOS price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.06
Diluted earnings per share over the trailing twelve months.
Beta
6.23
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.36 – $5.69
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $5.7 · P/B 3.18 · P/S 0.29.

Company News

9 captured
8-K filing — Vivos Therapeutics, Inc. (VVOS)SEC EDGAR · Jul 7, 2026, 9:29 PM
Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of Patients In TrialBenzinga · Jun 30, 2026, 12:50 PM
Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common StockBenzinga · Jun 22, 2026, 12:45 PM
Streeterville Extends Strategic Financing Deal With Streeterville Through August 31, Reaffirming Plan To Convert Up To $4.5M Debt Into Preferred And Common StockBenzinga · Jun 22, 2026, 12:40 PM
Vivos Therapeutics Announces Intent To File Registration For Proposed Rights OfferingBenzinga · Jun 11, 2026, 12:36 PM
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026Globenewswire Inc · Jun 8, 2026, 6:15 PM
Vivos Therapeutics Enters Senior Debt-to-Equity Exchange Agreement With Streeterville Capital For Up To $4.5MBenzinga · Jun 5, 2026, 12:50 PM
CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From ThursdayBenzinga · Jun 4, 2026, 12:45 PM
Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M EstimateBenzinga · May 20, 2026, 8:25 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock